Bolt Biotherapeutics, Inc.
BOLT
$5.26
-$0.02-0.29%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 2.17M | 1.80M | 1.22M | 0.00 | 1.14M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 2.17M | 1.80M | 1.22M | 0.00 | 1.14M |
| Cost of Revenue | 6.54M | 7.50M | 9.19M | 11.72M | 13.79M |
| Gross Profit | -4.37M | -5.69M | -7.97M | -11.72M | -12.64M |
| SG&A Expenses | 3.34M | 3.52M | 3.83M | 3.95M | 3.80M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 9.87M | 11.01M | 13.34M | 15.67M | 17.58M |
| Operating Income | -7.70M | -9.21M | -12.12M | -15.67M | -16.44M |
| Income Before Tax | -7.14M | -8.56M | -11.04M | -15.94M | -15.18M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.14M | -8.56M | -11.04M | -15.94M | -15.18M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.14M | -8.56M | -11.04M | -15.94M | -15.18M |
| EBIT | -7.70M | -9.21M | -12.12M | -15.67M | -16.44M |
| EBITDA | -7.41M | -8.86M | -11.72M | -15.24M | -16.00M |
| EPS Basic | -3.72 | -4.46 | -5.76 | -8.32 | -7.93 |
| Normalized Basic EPS | -2.33 | -2.79 | -3.60 | -4.80 | -4.96 |
| EPS Diluted | -3.72 | -4.46 | -5.76 | -8.32 | -7.93 |
| Normalized Diluted EPS | -2.33 | -2.79 | -3.60 | -4.80 | -4.96 |
| Average Basic Shares Outstanding | 1.92M | 1.92M | 1.92M | 1.91M | 1.91M |
| Average Diluted Shares Outstanding | 1.92M | 1.92M | 1.92M | 1.91M | 1.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |